NIH
Qiagen Preliminary Q1 Net Sales Up 5 Percent, Firm Raises 2025 EPS Estimate
The firm's guidance raise was seen by analysts as a positive indicator for companies with recurring NIH revenues.
Federal Funding Disruptions Could Impact Pipeline of Academic Life Science, Diagnostics Spinouts
Premium
Stakeholders expressed hope that the Trump administration's funding disruptions are temporary but noted academia's key role in generating investment opportunities.
The company said it expects its first quarter revenue to be down 10 percent to 15 percent year over year due in part to a decline in US academic sales.
Researchers Receive $8M NIH Grant to Evaluate Lucid Diagnostics Esophageal Precancer Test
The researchers will conduct a five-year study to evaluate the firm's collection device and test in patients without symptoms of chronic gastroesophageal reflux disease.
Through Agency-Funded Contractors, NIAID Aims to Help Bring Infectious Disease Tests to Market
Premium
The Diagnostics Development Services program is, so far, being used to help point-of-care testing firm Fluxergy bring to market a test for sexually transmitted infections.